Monograph Details
|
|
Nutrition
> Obesity
|
|
MERIDIA |
| Manufacturer |
|
Abbott Laboratories |
| Legal Classification |
|
CIV |
| Pharmacological Class |
|
Mixed neurotransmitter reuptake inhibitor. |
| Generic Name |
|
Sibutramine HCl monohydrate 5mg, 10mg, 15mg; caps. |
| Indications |
|
Adjunct to diet in the management of obesity in patients with initial body mass index ≥30kg/m2, or ≥27kg/m2 in presence of other risk factors. |
| Children |
|
<16years: not recommended. |
| Adults |
|
≥16years: Initially 10mg once daily. After 4 weeks, may titrate to 15mg once daily. |
| Contraindications |
|
During or within 2 weeks of MAOIs (eg, phenelzine, selegiline) or concomitant centrally-acting appetite suppressants. Anorexia or bulimia nervosa. Uncontrolled or poorly-controlled hypertension, or coronary artery disease, CHF, arrhythmias, or stroke: not recommended. |
| Precautions |
|
Exclude organic causes of obesity. Severe renal or hepatic dysfunction: not recommended. Do initial BP and pulse; monitor regularly during therapy; consider discontinuing or reducing dose for patients with sustained increases in either BP or pulse. Seizures (discontinue if occur). Hypertension. Narrow-angle glaucoma. Bleeding disorders. Elderly. Pregnancy (Cat.C), nursing mothers: not recommended. |
| Interactions |
|
See Contraindications. Avoid other serotonergic drugs (eg, SSRIs, venlafaxine); monitor if used together; possible serotonin syndrome with these and with sumatriptan, dihydroergotamine, some opioids (eg, dextromethorphan, meperidine, pentazocine, fentanyl), lithium, or tryptophan. Caution with other CNS-active drugs or drugs that can raise BP or pulse (eg, decongestants). Possible interaction with ketoconazole, erythromycin, others metabolized by CYP3A4. Excessive alcohol: not recommended. Caution with oral anticoagulants, platelet inhibitors. |
| Adverse Reactions |
|
Dry mouth, anorexia, insomnia, constipation, headache, increased appetite, dizziness, nervousness, GI upset, gallstones, increased BP and/or pulse, mydriasis, others. |
| How Supplied |
|
Caps—30, 100 |
|
|
|
|
